Strata Critical Medical Q3 revenue beats estimates; announces buyback

Overview

• US medical logistics and clinical services firm's Q3 revenue rose 50% yr/yr, beating analyst expectations

• Adjusted EBITDA more than doubled yr/yr, driven by clinical segment acquisitions

• Company authorized $20 mln share repurchase program

Outlook

• Strata reiterates 2026 revenue guidance of $285-295 mln

• Company maintains 2026 adjusted EBITDA outlook at $33-35 mln

• Strata expects 2026 free cash flow, before aircraft and engine acquisitions, of $15-22 mln

Result Drivers

• CLINICAL ACQUISITIONS - Co said revenue growth was driven by a full quarter contribution from Keystone acquisition and three acquisitions completed in Q2

• LOGISTICS SEGMENT - Logistics revenue declined yr/yr, attributed to increased fuel surcharge pass through revenue and shorter average donor-recipient distances, resulting in lower margins on owned aircraft

• CLINICAL MARGIN EXPANSION - Clinical gross margin increased yr/yr, supported by acquisitions and modest organic growth, though sequential margin declined due to staff and training investments

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

• Wall Street's median 12-month price target for Strata Critical Medical, Inc. is $8.75, about 104.4% above its November 2 closing price of $4.28

• The stock recently traded at 82 times the next 12-month earnings vs. a P/E of 147 three months ago

Reuters Recommended Reads

• Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

• Nov 3 - Amneal Q3 revenue beats estimates on affordable medicines growth; outlook raised

• Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)